The following communication was sent to certain beneficial holders of its ordinary shares by Teva
Pharmaceutical Industries Limited:
|
|
|
|
|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
2023 ANNUAL MEETING OF SHAREHOLDERS
June 15, 2023 4:00
p.m. (Israel time) At Tevas Executive Offices
124 Dvora HaNevia Street
Tel Aviv, 6944020 Israel
Participation instructions for the Teva Pharmaceutical Industries Limited 2023 Annual Meeting of Shareholders are available in the proxy
statement which can be viewed at www.tevapharm.com/2023proxymaterials. |
Important Notice Regarding the
Availability of Proxy Materials for the
Shareholder Meeting to be Held on June 15, 2023.
Notice is hereby given that the 2023 Annual Meeting of Shareholders (the meeting) of Teva Pharmaceutical Industries Limited (Teva)
will be held at 124 Dvora HaNevia Street, Tel Aviv, 6944020, Israel on June 15, 2023 at 4:00 p.m. (Israel time).
This communication
presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. This is not a form for
voting.
The Notice of Annual Meeting of Shareholders and Proxy Statement and Annual Report are available at www.tevapharm.com/2023proxymaterials.
If you want to receive a paper copy or an e-mail with links to the electronic materials, you must request
one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before May 25, 2023 to facilitate timely delivery. Unless requested, you will not otherwise receive a paper or email copy.
Matters intended to be acted upon at the meeting are listed below.
1. |
To appoint the following persons: Dr. Sol J. Barer, Michal Braverman-Blumenstyk and Janet S. Vergis
to serve on the Board of Directors until our 2026 annual meeting of shareholders. |
2. |
To approve, on a non-binding advisory basis, the compensation for
Tevas named executive officers. |
3. |
To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as
Tevas independent registered public accounting firm until Tevas 2024 annual meeting of shareholders. |
In addition,
shareholders will consider Tevas annual consolidated financial statements for the year ended December 31, 2022.
The Board of Directors
recommends that you vote FOR all proposals.
To request paper copies of the proxy materials, which include the proxy card,
proxy statement and annual report, please contact us via:
|
|
|
Telephone Call our proxy solicitor, MacKenzie Partners, Inc., toll free within the U.S. at +1 (800)
322-2885 or outside the U.S. at + 1 (212) 929-5500. In Israel, call us at +972 (3) 914-8262. |